Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro

International Journal of Pharmaceutics

Volumn 422, Issue 1-2, 2012, Pages 409-417

  Wang, Yongzhong ^a   Chen, Li ^a   Ding, Yunfei ^a   Yan, Weili ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Anthracycline; Drug delivery system; Leukemia; Micelle; Oxidized phospholipid; pH sensitive

Indexed keywords

1 PALMITOYL 2 AZELAOYL SN GLYCERO 3 PHOSPHOCHOLINE; CHOLINE DERIVATIVE; DOXORUBICIN; DRUG VEHICLE; IDARUBICIN; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; ENDOSOME; EVAPORATION; HYDROPHOBICITY; LEUKEMIA CELL; MICELLE; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; STATIC ELECTRICITY; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IDARUBICIN; KINETICS; LEUKEMIA; MICE; MICELLES; OXIDATION-REDUCTION; PARTICLE SIZE; PHOSPHORYLCHOLINE; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84655167948     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.10.029     Document Type: Article

References (28)

1. J.O. Kim, A.V. Kabanov, and T.K. Bronich Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin J. Control. Release 138 2009 197 204
2. J.Y. Liu, Y. Pang, W. Huang, X.Y. Zhu, Y.F. Zhou, and D.Y. Yan Self-assembly of phospholipid-analogous hyperbranched polymers nanomicelles for drug delivery Biomaterials 31 2010 1334 1341
3. Z.L. Tyrrell, Y.Q. Shen, and M. Radosz Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers Prog. Polym. Sci. 35 2010 1128 1143
4. V. Alakhov, E. Klinski, S.M. Li, G. Pietrzynski, A. Venne, and E. Batrakova Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials Colloid Surf. B 16 1999 113 134 (Pubitemid 29486800)
5. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, and D. Jowle Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer Br. J. Cancer 90 2004 2085 2091 (Pubitemid 38869710)
6. A.N. Lukyanov, and V.P. Torchilin Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs Adv. Drug Deliv. Rev. 56 2004 1273 1289 (Pubitemid 38510474)
7. O.M. Koo, I. Rubinstein, and H. Onyuksel Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine Nanomedicine 1 2005 77 84 (Pubitemid 43963604)
8. J.P. Mattila, K. Sabatini, and P.K.J. Kinnunen Oxidized phospholipids as potential novel drug targets Biophys. J. 93 2007 3105 3112 (Pubitemid 350097101)
9. G. Vitiello, D. Ciccarelli, O. Ortona, and G. D'Errico Microstructural characterization of lysophosphatidylcholine micellar aggregates: the structural basis for their use as biomembrane mimics J. Colloid Interface Sci. 336 2009 827 833
10. G.O. Fruhwirth, A. Loidl, and A. Hermetter Oxidized phospholipids: from molecular properties to disease Biochim. Biophys. Acta 1772 2007 718 736 (Pubitemid 46891216)
11. V.N. Bochkov, O.V. Oskolkova, K.G. Birukov, A.L. Levonen, C.J. Binder, and J. Stockl Generation and biological activities of oxidized phospholipids Antioxid. Redox Signal. 12 2010 1009 1059
12. A.H. Pande, S. Kar, and R.K. Tripathy Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids Biochim. Biophys. Acta 1798 2010 442 452
13. H. Khandelia, O.G. Mouritsen, and Lipid Gymnastics Evidence of complete acyl chain reversal in oxidized phospholipids from molecular simulations Biophys. J. 96 2009 2734 2743
14. P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, and H.C. Ledebur Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 5 2009 151 161
15. Y.Z. Wang, L. Yu, L.M. Han, X.Y. Sha, and X.L. Fang Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines Int. J. Pharm. 337 2007 63 73 (Pubitemid 46756036)
16. Y.C. Chen, S.R. Bathula, J. Li, and L. Huang Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 285 2010 22639 22650
17. J.S. Cheng, and Y.P. Chen Correlation of the critical micelle concentration for aqueous solutions of nonionic surfactants Fluid Phase Equilib. 232 2005 37 43
18. W.W. Gao, J.M. Chan, and O.C. Farokhzad pH-responsive nanoparticles for drug delivery Mol. Pharm. 7 2010 1913 1920
19. R. Chen, L. Yang, and T.M. McIntyre Cytotoxic phospholipid oxidation products. Cell death from mitochondrial damage and the intrinsic caspase cascade J. Biol. Chem. 282 2007 24842 24850 (Pubitemid 47347534)
20. S.R. Bauer, K.L. Holmes, H.C. Morse, and M. Potter Clonal relationship of the lymphoblastic cell-line P388 to the macrophage cell-line P388d1 as evidence by immunoglobulin gene rearrangements and expression of cell-surface antigens J. Immunol. 136 1986 4695 4699 (Pubitemid 16090696)
21. M. Lechleitner, B. Auer, U. Zilian, F. Hoppichler, M. Schirmer, and B. Foger The immunosuppressive substance 2-chloro-2-deoxyadenosine modulates lipoprotein metabolism in a murine macrophage cell-line (P388 cells) Lipids 29 1994 627 633 (Pubitemid 24282371)
22. W.S. Lim, P.G. Tardi, N. Dos Santos, X.W. Xie, M.N. Fan, and B.D. Liboiron Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts Leukemia Res. 34 2010 1214 1223
23. L. Belov, O. de la Vega, C.G. dos Remedios, S.P. Mulligan, and R.I. Christopherson Immunophenotyping of leukemias using a cluster of differentiation antibody microarray Cancer Res. 61 2001 4483 4489 (Pubitemid 32685778)
24. Y. Xu, R.W. McKenna, K.S. Wilson, N.J. Karandikar, R.A. Schultz, and S.H. Kroft Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation Leukemia 20 2006 1321 1324 (Pubitemid 43905847)
25. D.E. Banker, S.J. Mayer, H.Y. Li, C.L. Willman, F.R. Appelbaum, and R.A. Zager Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells Blood 104 2004 1816 1824 (Pubitemid 39202292)
26. U. Scherf, D.T. Ross, M. Waltham, L.H. Smith, J.K. Lee, and L. Tanabe A gene expression database for the molecular pharmacology of cancer Nat. Genet. 24 2000 236 244 (Pubitemid 30132190)
27. R. Chen, A.E. Feldstein, and T.M. McIntyre Suppression of mitochondrial function by oxidatively truncated phospholipids is reversible, aided by bid, and suppressed by Bcl-XL J. Biol. Chem. 284 2009 26297 26308
28. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 2009 579 591